Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study

Launched by ZHUJIANG HOSPITAL · Mar 2, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to monitor patients who have had surgery for hepatocellular carcinoma (HCC), a type of liver cancer. The researchers want to see if testing urine can help predict if the cancer might come back after surgery, and if this method can do so earlier than traditional imaging tests like scans. By understanding the presence of minimal residual disease (MRD), they hope to improve early treatment strategies for patients recovering from HCC surgery.

To participate in this study, patients should have been diagnosed with early-stage HCC and be eligible for surgery without having received other cancer treatments beforehand. This trial is open to adults aged 65 to 74 and aims to recruit individuals of all genders. Participants will provide urine samples for testing and will be monitored over time to gather important information about their recovery. This research could lead to better ways to manage HCC after surgery, helping doctors act quickly if there are signs of recurrence.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with hepatocellular carcinoma whose tumor stage at the time of initial diagnosis is consistent with BCLC staging 0/stage A/stage B, who can undergo radical surgical resection, and who have not received other antitumor therapy preoperatively.
• Exclusion Criteria:
• • Unable to provide specimens for testing such as urine proteomics; patients with a previous diagnosis of renal or urologic disease, two or more tumors at the same time; patients with non-primary foci of liver disease. Previously received anti-tumor therapy such as targeted immunotherapy.